Patents Issued in July 9, 2020
  • Publication number: 20200214989
    Abstract: Supramolecular particle compositions based on medicinal natural products (MNPs), their synthetic analogs and derivatives, and methods to prepare and use them are provided. Five classes of MNPs and their derivatives including diterpene resin acid, phytosterol, lupane-type pentacyclic triterpene, oleanane-type pentacyclic tritepene, and lanostane-type triterpene form functional nano- or micro-structures that are stable to strong acidic environment and effectively penetrate the gastrointestinal tract. Therapeutic, prophylactic, or diagnostic agents that generally have poor intestinal permeability are converted to bioavailable forms when delivered with these supramolecular particles. Among many others, small compound chemotherapeutic agents and peptide therapeutics encapsulated therein have a much greater plasma concentration following oral administration, and effectively controls and treat symptoms associated with tumors or diabetes.
    Type: Application
    Filed: June 21, 2018
    Publication date: July 9, 2020
    Inventors: Jiangbing Zhou, Xin Yang, Chao Ma
  • Publication number: 20200214990
    Abstract: A tadalafil orally dissolving film and a preparation method thereof are provided. The tadalafil orally dissolving film consisting of specific components is prepared through a conventional process. Particularly, the tadalafil orally dissolving film is prepared by tadalafil, film-forming material, plasticizer, correctant, colorant and aromatic, wherein the film-forming material includes components of: (a) at least one member selected from polysaccharide; (b) at least one member selected from organic acid; and (c) at least one member selected from hydroxyalkyl cellulose. Compared with prior art, the tadalafil orally dissolving film provided by the present invention has an easy preparation process, no specific requirement on production devices and a storing stability, and is easy to reproduce, has a low requirement on storage conditions, and is easy to package, transport and store.
    Type: Application
    Filed: April 30, 2017
    Publication date: July 9, 2020
    Inventors: Xinhua Fan, Yongrui Tu, Jintao Zhang, Tack Soo Nam, Yun He, Yueyu Zhou, Ji Zhu, Mingjie Zhang
  • Publication number: 20200214991
    Abstract: Provided is an adhesive sheet for adhesion to the skin, which has sufficient adhesiveness and causes low skin irritation. The adhesive sheet comprises a support and an adhesive layer formed on the support, in which the adhesive layer contains at least a thermoplastic elastomer and a non-volatile hydrocarbon oil. Further provided is a transdermal absorption preparation having sufficient adhesiveness and drug releaseability and causes low skin irritation. The transdermal absorption preparation comprises an adhesive sheet as described herein and a drug or a pharmaceutically acceptable salt thereof that is contained in the adhesive layer of the sheet.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Applicant: KM Transderm Ltd.
    Inventors: Hiroyuki OGINO, Sadao YUKIMOTO, Atsuyo HAMADA, Mitsuji AKAZAWA, Masaoki GOTO
  • Publication number: 20200214992
    Abstract: A patch preparation which can produce the effect for preventing any problems due to the misuse of the patch preparation, includes a support and a plaster wherein the plaster includes a) an aliphatic compound with hydrophilic group which is in solid state at room temperature, b) a non-aqueous adhesive, and c) a solvent with a vapor pressure of 1 kPa or more at 20° C.
    Type: Application
    Filed: September 21, 2018
    Publication date: July 9, 2020
    Inventor: Hidetoshi HAMAMOTO
  • Publication number: 20200214993
    Abstract: Provided are methods and devices useful for treating a respiratory disease or disorder involving the central or upper airways. The methods and devices deliver to central or upper airways of a subject a vapor or aerosol comprising an effective amount of an active ingredient selected from the group consisting of menthol, menthone, neomenthol, isomenthol, and menthofuran. The methods are useful for treating conditions including cough, asthma, bronchitis, and allergic rhinitis.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 9, 2020
    Inventor: Adriane Fugh-Berman
  • Publication number: 20200214994
    Abstract: A composition for treating the symptoms of a hangover. The composition is provided in the form of a capsule, pill, liquid, powder for mixing, or patch. The composition includes a therapeutically effective amount of cannabidiol, an antioxidant blend, a detox blend, and a hydration blend. The antioxidant blend includes prickly pear, acai berry extract, and taurine. The detox blend includes milk thistle, dihydromyricetin, glutamine, branched chain amino acids, inositol, and pepper. The hydration blend includes electrolytes, vitamins, and N-acetyl cysteine.
    Type: Application
    Filed: January 6, 2020
    Publication date: July 9, 2020
    Applicant: JONAND4, LLC
    Inventor: Jonathan B. Andry
  • Publication number: 20200214995
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 9, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • Publication number: 20200214996
    Abstract: The present disclosure relates to compositions, including, hydrogel compositions useful as topical analgesics including cannabinoids and menthol where the menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid. The present disclosure also disclosure relates to compositions, including, hydrogel compositions useful as topical analgesics including cannabinoids and menthol as well as carboxymethyl cellulose, carrageenan and a cross-linking agent.
    Type: Application
    Filed: March 2, 2020
    Publication date: July 9, 2020
    Inventor: Babak Ghalili
  • Publication number: 20200214997
    Abstract: The invention provides a method for treating a neurodegenerative disorder in a subject in need of such treatment, comprising administrating to said subject a compound with (substituted phenyl)-propenal moiety.
    Type: Application
    Filed: December 31, 2019
    Publication date: July 9, 2020
    Inventor: Hardy W. Chan
  • Publication number: 20200214998
    Abstract: The disclosure provides a method for treating a brain cancer in a subject in need of such treatment, comprising administrating to said subject a compound with (substituted phenyl)-propenal moiety.
    Type: Application
    Filed: December 31, 2019
    Publication date: July 9, 2020
    Inventors: Hardy W. Chan, Tzu Chi Chen
  • Publication number: 20200214999
    Abstract: The disclosure provides a method for treating an inflammatory disorder relating an inflammatory cytokine overexpression in a subject in need of such treatment, comprising administrating to said subject a compound with (substituted phenyl)-propenal moiety.
    Type: Application
    Filed: December 31, 2019
    Publication date: July 9, 2020
    Inventor: Hardy W. Chan
  • Publication number: 20200215000
    Abstract: A method of treating chronic kidney disease including administering to a subject in need thereof a combination of a vitamin K and a phosphate binder.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 9, 2020
    Inventors: Daniel H. ROSENBAUM, Lee M. TECHNER
  • Publication number: 20200215001
    Abstract: Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative DNA damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described herein.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Inventors: Mark R. Kelley, Michael R. Vasko
  • Publication number: 20200215002
    Abstract: A pharmaceutical composition containing cinacalcet or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. A pharmaceutical composition containing cinacalcet or pharmaceutically acceptable salts thereof having a particle size distribution D90 equal to or less than 20 ?m, D50 equal to or less than 10 ?m, and D10 equal to or less than 5 ?m and one or more and binders in an amount of 0.9% w/w or less, relative to the total weight of composition, where the composition is not free of binder and that the total amount of binder does not exceed 0.9% w/w relative to the total weight of the composition.
    Type: Application
    Filed: August 13, 2018
    Publication date: July 9, 2020
    Applicant: UNICHEM LABORATORIES LTD
    Inventors: Dhananjay SATHE, Srikant PIMPLE, Pravin Kumar MAURYA
  • Publication number: 20200215003
    Abstract: An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 9, 2020
    Applicant: GRÜNENTHAL GMBH
    Inventors: Thomas CHRISTOPH, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS, Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Petra BLOMS-FUNKE, Klaus SCHIENE, Ulrich FEIL
  • Publication number: 20200215004
    Abstract: The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 9, 2020
    Inventors: Prem Sagar Akasapu, Kumaresh Soppimath, Reema Ajitkumar Puri, Iouri V. Ilitchev, Milan Patel, Pooja H. Tendulkar
  • Publication number: 20200215005
    Abstract: The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 9, 2020
    Inventors: Prem Sagar Akasapu, Kumaresh Soppimath, Reema Ajitkumar Puri, Iouri V. Ilitchev, Milan Patel, Pooja H. Tendulkar
  • Publication number: 20200215006
    Abstract: The present disclosure provides novel topical compositions comprising endoxifen and salts and solvates thereof and methods for making the compositions. Certain compounds have been combined to make a stable topical compositions comprising endoxifen. The present disclosure also provides methods for treatment of hormone-dependent breast and hormone-dependent reproductive tract disorders.
    Type: Application
    Filed: September 10, 2018
    Publication date: July 9, 2020
    Applicant: Atossa Therapeutics, Inc.
    Inventors: Steven C. Quay, Avadhesh S. Kushwaha, Edward T. Kisak, John M. Newsam
  • Publication number: 20200215007
    Abstract: The present invention is directed to compositions and formulations for hair growth. The non-aqueous, preservative-free formulations are useful for the growth of hair, eyebrows and eyelash in a variety of setting. Also provided herein are non-aqueous, preservative-free formulations and methods for the treatment of dry-eye and related symptoms.
    Type: Application
    Filed: June 30, 2017
    Publication date: July 9, 2020
    Inventors: Weizhen WANG, David F. WOODWARD
  • Publication number: 20200215008
    Abstract: Administration of a salt of bicyclo [2.2.2] octane-2-carbonic acid reduces dysphoria in dysphoric subjects, ameliorates ethanol craving in alcoholics, reduces the erythrocyte sedimentation rate and the level of liver function markers (AST, ALT, and bilirubin) in human subjects, and reduces the number or strength of seizures in epileptics.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Inventor: Susanna A. Saakian
  • Publication number: 20200215009
    Abstract: This invention provides systems, methods and compositions for the prevention of diseases caused by amyloid based deposits of proteins. This invention teaches procedures and therapeutic models for controlling amyloids and related plaque deposits as applicable to common diseases including, but not limited to: Alzheimer's, cardiovascular, stroke, arterial sclerosis, etc. By addressing plaque development at its earliest stage involving protein-protein interaction, ongoing plaque growth is arrested or substantially decreased while the balance of plaque deposition/management for expulsion of existing plaques is switched to favor the body's natural aberrant protein removal mechanisms. The preferred embodiment implements a dual approach for: a) attacking protein dimerization and oligomerization that serves as the cornerstone of the disease, and b) rebalancing the body's natural processes to enhance removal of existing plaques through inflammation management in concert with cessation of ongoing plaque formation.
    Type: Application
    Filed: September 23, 2017
    Publication date: July 9, 2020
    Inventor: Richard Postrel
  • Publication number: 20200215010
    Abstract: The invention provides methods for treating or preventing developmental disorders associated with mutations in the OCD1 gene.
    Type: Application
    Filed: September 4, 2019
    Publication date: July 9, 2020
    Inventors: Andre BACHMANN, Caleb Bupp, Surender Rajasekaran
  • Publication number: 20200215011
    Abstract: Compositions comprising an amino acid component including: L-histidine, L-isoleucine, L-leucine, L-lysine, L-phenylalanine, L-threonine, L-tryptophan, L-valine and L-arginine and optimized levels of L-methionine. L-tryptophan content may also be elevated and optimized, and additional amino acids including arginine, L-arginine, L-citrulline, L-carnitine and L-cysteine may optionally be present. Methods of treating muscle, wounds, surgical procedures, skin conditions and other conditions using such compositions are also provided.
    Type: Application
    Filed: August 16, 2018
    Publication date: July 9, 2020
    Applicant: CALWOOD NUTRITIONALS, LLC
    Inventor: Gary CALTON
  • Publication number: 20200215012
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 9, 2020
    Inventors: Adam HELLER, Ephraim HELLER, Karl Göran WESTERBERG, John SPIRIDIGLIOZZI
  • Publication number: 20200215013
    Abstract: Decanoic acid for use in treating epilepsy wherein the decanoic acid is used in combination with perampanel, or a pharmaceutically acceptable salt thereof, or wherein the decanoic acid is used in combination with an AMPA receptor inhibitor that binds to the same AMPA receptor site as perampanel.
    Type: Application
    Filed: June 28, 2018
    Publication date: July 9, 2020
    Inventors: Robin Simon Brooke Williams, Matthew Walker
  • Publication number: 20200215014
    Abstract: A method of treating or preventing cardiovascular disease which comprises administering a therapeutically effective amount of at least one n-3 DPA-derived resolvin and/or upregulating or increasing the biosynthesis or activity of at least one n-3 DPA-derived resolvin. n-3 DPA-derived resolvins are normally regulated diurnally in the body and are linked to activation of platelets and leucocytes and formation of platelet-leukocyte aggregates. Dysfunctional regulation of n-3 DPA-derived resolvins may lead to systemic inflammation because of excessive inflammation-inducing eicosanoids, especially in the early hours of the morning. Further, decreased 5-LOX/15-LOX expression and increased systemic adenosine concentrations are found to be associated with reduced resolvin levels and increased risk of cardiovascular disease. n-3 DPA-derived resolvins are administered to achieve maximum absorption in the early hours.
    Type: Application
    Filed: September 19, 2018
    Publication date: July 9, 2020
    Inventors: Jesmond Dalli, Romain Alexandre Colas, Patricia Regina Souza
  • Publication number: 20200215015
    Abstract: The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.
    Type: Application
    Filed: September 10, 2018
    Publication date: July 9, 2020
    Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventor: Rheal A. TOWNER
  • Publication number: 20200215016
    Abstract: Described herein is the surprising discovery that ketone bodies protect cell and tissues from ionizing radiation. Based on this finding, methods of protecting animal tissue and cells from damage caused by radiation exposure are disclosed which include, contacting the tissue with a therapeutically effective amount of an agent including at least one ketone ester, thereby protecting the tissue from radiation damage. Ketone esters can be used to minimize, reduce and/or prevent tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage.
    Type: Application
    Filed: October 7, 2019
    Publication date: July 9, 2020
    Inventors: Richard Lewis Veech, Kieran Clarke
  • Publication number: 20200215017
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Publication number: 20200215018
    Abstract: A method of treating cancer which comprises administering to a cancer patient a therapeutically effective amount of a gold or platinum based drug that has less toxicity and a different mechanism of action to kill the tumor cells than cisplatin.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 9, 2020
    Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Mohammad Hassan Beyzavi, Hamid Reza Shahsavari
  • Publication number: 20200215019
    Abstract: The disclosure relates to ferric citrate tablets and dosage forms.
    Type: Application
    Filed: April 5, 2019
    Publication date: July 9, 2020
    Inventor: Henry Trong Le
  • Publication number: 20200215020
    Abstract: A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof are disclosed. The pharmaceutical composition includes furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and a cyclodextrin.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 9, 2020
    Inventor: Pieter Muntendam
  • Publication number: 20200215021
    Abstract: The present disclosure targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.
    Type: Application
    Filed: February 18, 2020
    Publication date: July 9, 2020
    Inventor: Steven Baranowitz
  • Publication number: 20200215022
    Abstract: The present disclosure describes various novel compositions and methods, wherein said compositions and methods comprise CBD and THC in certain relative ratios.
    Type: Application
    Filed: December 20, 2017
    Publication date: July 9, 2020
    Inventors: Catherine JACOBSON, Caleb Joshua EADES
  • Publication number: 20200215023
    Abstract: The disclosure demonstrates the role of mast cell stabilizers in treating rosacea. The disclosure also shows the role of mast cells, cathelicidin, serine protease and/or vitamin D3 in rosacea pathology and the use of antagonists and inhibitors thereof to treat rosacea.
    Type: Application
    Filed: September 19, 2019
    Publication date: July 9, 2020
    Inventors: Richard L. Gallo, Anna Di Nardo, Yumiko Muto
  • Publication number: 20200215024
    Abstract: Compositions for reducing alcohol consumption and/or treating alcohol hangover contain a first active agent containing at least one cannabinoid compound, a second active agent effective in reducing one or more symptoms of alcohol hangover, and a carrier. In some forms, the carrier is an anhydrous liposphere concentrate (ALC) containing a lipid system including lipid, optionally a water miscible solvent, and one or more surfactants and/or one or more phospholipids. In a preferred embodiment, the carrier spontaneously forms a nanodispersion of nanolipids or lipospheres, upon addition to an aqueous medium, which contain the cannabinoid compound and other compounds from the active agents. The compositions can be used to form oral dosage formulations for delivery of the cannabinoid compound.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 9, 2020
    Inventors: Kayla Berman, Andra Weissberger, Abraham J. Domb
  • Publication number: 20200215025
    Abstract: The invention relates to methods for treating or minimising nervous system excitotoxicity, or a condition associated with excitotoxicity, through inhibition of calcium release and/or calcium uptake from a cell, in an individual utilising a compound according to general formula (1).
    Type: Application
    Filed: September 17, 2018
    Publication date: July 9, 2020
    Inventors: Graham KELLY, Benny EVISON, Gary HOUSLEY
  • Publication number: 20200215026
    Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations.
    Type: Application
    Filed: December 17, 2019
    Publication date: July 9, 2020
    Inventors: Earnie BLACKMON, Tony VERZURA
  • Publication number: 20200215027
    Abstract: Nanoemulsion compositions, processes, and methods that include dihydromyricetin (DHM).
    Type: Application
    Filed: December 20, 2019
    Publication date: July 9, 2020
    Inventors: Robert K. PRUD'HOMME, Brooks POWELL, Chang TIAN, Nicholas CAGGIANO, Vikram PANSARE
  • Publication number: 20200215028
    Abstract: A topical ophthalmic anesthetic composition includes a formulation with an amount of articaine to provide anesthetic properties when applied topically to the eye, and a pH, viscosity, osmolality, dissociation constant, and additives such as antioxidants, buffers, methylcellulose, to achieve efficacy and safety. The composition can contain articaine in amounts of about 4.0% w/v to about 12.0% w/v and have a pH of about pH 3.5 to pH 7.0. The buffer can be borate/mannitol complex obtained from boric acid or salt thereof and D-mannitol. The articaine formulations can achieve adequate anesthesia of the internal aspect of the eye wall by topical application, without the use of an injectable anesthetic. Exemplary implementations of the disclosure include formulations include articaine in an amount of at least 7.0% w/v, where the formulation is an aqueous solution, a gel, an ointment, or in an encapsulated form.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 9, 2020
    Inventor: Martin Uram
  • Publication number: 20200215029
    Abstract: The disclosure relates to application of AMD3100 or a pharmaceutically acceptable salt thereof in preparation of a drug for treating and/or preventing cachexia and a pharmaceutical composition thereof as well as a method for treating and/or preventing cachexia using the same.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 9, 2020
    Inventors: Peng Xiang, Jiancheng Wang
  • Publication number: 20200215030
    Abstract: An object of the present invention is to provide a drug which prevents progress of Alzheimer's disease and a method of preventing progress of Alzheimer's disease. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy and is useful as an agent for preventing or treating brain atrophy. Brain atrophy observed in aging or neurodegenerative diseases can be prevented or treated by administering 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
    Type: Application
    Filed: June 1, 2018
    Publication date: July 9, 2020
    Applicant: FUJIFILM Toyama Chemical Co., Ltd.
    Inventors: Hiroshi KOBAYASHI, Yoshihiko MATSUMOTO
  • Publication number: 20200215031
    Abstract: A method of treating cancer is provided. The method includes administering to a subject in need thereof an effective amount of a compound selected from the group consisting of a glycogen phosphorylase inhibitor, a glycogen synthase inhibitor, a glycogen degradation molecule, an anti-sense oligonucleotide that down-regulates glycogen synthesis, and combinations thereof, where the cancer includes elevated levels of glycogen.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 9, 2020
    Inventors: Matthew S. Gentry, Ramon C. Sun, Lyndsay EA Young
  • Publication number: 20200215032
    Abstract: Among the various aspects of the present disclosure is the provision of methods and compositions for improving exercise endurance, performance, or tolerance using an S1P inhibiting agent.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 9, 2020
    Applicant: Washington University
    Inventors: Rita Brookheart, Brian Finck
  • Publication number: 20200215033
    Abstract: The invention relates to the alkaloids mesembranol or mesembrenol, or pharmaceutical acceptable salts or complexes thereof, for use in the prophylaxis or treatment of a disease that responds to treatment with an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist. The prophylaxis or treatment attenuates AMPA mediated neurotransmission in the hippocampus of a subject.
    Type: Application
    Filed: July 25, 2018
    Publication date: July 9, 2020
    Applicant: HG&H Pharmaceuticals (Pty) Ltd
    Inventor: Wilfried Dimpfel
  • Publication number: 20200215034
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 9, 2020
    Inventors: Gretchen BAIN, Jillian Frances EVANS, John Howard HUTCHINSON, David LONERGAN
  • Publication number: 20200215035
    Abstract: Prodrugs of colchicine, de-acetyl colchicine, colcemid, and nocodazole are provided as therapies for the treatment of diseases ameliorated by the inhibition of microtubule polymerization.
    Type: Application
    Filed: June 19, 2018
    Publication date: July 9, 2020
    Inventors: Joseph Pao Yung KAO, Christopher William WARD, Ramzi KHAIRALLAH
  • Publication number: 20200215036
    Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly RLK (TXK). The present invention is directed to a compound of Formula (I) or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.
    Type: Application
    Filed: August 21, 2018
    Publication date: July 9, 2020
    Inventors: Alain Laurent, Stephen J. Morris
  • Publication number: 20200215037
    Abstract: Disclosed herein are methods for increasing circulating mesenchymal stem cells by administering a compound having the general formula 1 as defined herein, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 9, 2018
    Publication date: July 9, 2020
    Inventors: Kevin J. GAFFNEY, Kathleen E. RODGERS, Maira SOTO, Michael WEINBERG
  • Publication number: 20200215038
    Abstract: Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.
    Type: Application
    Filed: August 27, 2019
    Publication date: July 9, 2020
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leonard ZON, Richard M. White